Capital Group Private Client Services, Inc. Bei Gene, Ltd. Transaction History
Capital Group Private Client Services, Inc.
- $10.6 Billion
- Q2 2025
A detailed history of Capital Group Private Client Services, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital Group Private Client Services, Inc. holds 148,613 shares of BGNE stock, worth $33.7 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
148,613
              Previous 152,156
              
        
           2.33%
        
      
          
        Holding current value
$33.7 Million
            Previous $34.5 Million
            
        
           2.33%
        
      
          
        % of portfolio
0.32%
            Previous 0.36%
          
        Shares
	  16 transactions
	
  Others Institutions Holding BGNE
# of Institutions
286Shares Held
32.3MCall Options Held
113KPut Options Held
106K- 
    
      Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
- 
    
      Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
- 
    
      Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
- 
    
      Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
- 
    
      Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...